TCM
Tekla Capital Management Portfolio holdings
AUM
$2.56B
This Quarter Return
+0.51%
1 Year Return
+18.15%
3 Year Return
+62.34%
5 Year Return
+140.22%
10 Year Return
+499.57%
AUM
$2.57B
AUM Growth
+$2.57B
(-0.83%)
Cap. Flow
+$49.2M
Cap. Flow
% of AUM
1.91%
Top 10 Holdings %
Top 10 Hldgs %
39.02%
Holding
198
New
37
Increased
49
Reduced
41
Closed
10
Top Buys
| 1 |
Pfizer
PFE
|
$38.2M |
| 2 |
Johnson & Johnson
JNJ
|
$20.1M |
| 3 |
Esperion Therapeutics
ESPR
|
$13.7M |
| 4 |
Nektar Therapeutics
NKTR
|
$13.2M |
| 5 |
Bristol-Myers Squibb
BMY
|
$11.2M |
Top Sells
| 1 |
Gilead Sciences
GILD
|
$34.4M |
| 2 |
Amgen
AMGN
|
$27.5M |
| 3 |
Biogen
BIIB
|
$18.3M |
| 4 |
ALXN
Alexion Pharmaceuticals Inc
ALXN
|
$17.9M |
| 5 |
BioMarin Pharmaceuticals
BMRN
|
$16.9M |
Sector Composition
| 1 | Healthcare | 93.47% |
| 2 | Real Estate | 2.71% |
| 3 | Financials | 0.31% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Gilead Sciences
GILD
$140B
| $156M | 6.05% | 2,063,699 -456,582 | -18% | -$34.4M |
|
|
CELG
2
DELISTED
Celgene Corp
CELG
| $121M | 4.69% | 1,352,842 -161,062 | -11% | -$14.4M |
|
|
3
Amgen
AMGN
$155B
| $119M | 4.65% | 700,588 -161,586 | -19% | -$27.5M |
|
|
4
Johnson & Johnson
JNJ
$427B
| $114M | 4.45% | 893,082 +156,950 | +21% | +$20.1M |
|
|
5
Biogen
BIIB
$19.4B
| $104M | 4.03% | 378,703 -66,904 | -15% | -$18.3M |
|
6
Vertex Pharmaceuticals
VRTX
$100B
| $100M | 3.89% | 614,084 -29,678 | -5% | -$4.84M |
|
7
UnitedHealth
UNH
$281B
| $75.4M | 2.93% | 352,317 +46,431 | +15% | +$9.94M |
|
|
8
Pfizer
PFE
$141B
| $72.8M | 2.83% | 2,051,943 +1,076,856 | +110% | +$38.2M |
|
9
Viatris
VTRS
$12.3B
| $71.1M | 2.77% | 1,726,967 +123,855 | +8% | +$5.1M |
|
10
Merck
MRK
$210B
| $69.9M | 2.72% | 1,284,022 -38,173 | -3% | -$2.08M |
|
11
Illumina
ILMN
$15.8B
| $69.7M | 2.71% | 294,892 +9,101 | +3% | +$2.15M |
|
|
ALXN
12
DELISTED
Alexion Pharmaceuticals Inc
ALXN
| $55.6M | 2.16% | 498,975 -160,643 | -24% | -$17.9M |
|
13
Incyte
INCY
$16.5B
| $53.8M | 2.09% | 645,442 -47,833 | -7% | -$3.99M |
|
14
Regeneron Pharmaceuticals
REGN
$61.5B
| $48.1M | 1.87% | 139,560 -30,956 | -18% | -$10.7M |
|
15
Abbott
ABT
$231B
| $47.9M | 1.86% | 798,619 | – | – |
|
16
AbbVie
ABBV
$372B
| $42.7M | 1.66% | 450,738 +104,425 | +30% | +$9.88M |
|
17
Medtronic
MDT
$119B
| $41.9M | 1.63% | 522,211 +16,185 | +3% | +$1.3M |
|
|
AGN
18
DELISTED
Allergan plc
AGN
| $41.9M | 1.63% | 248,836 +40,656 | +20% | +$6.84M |
|
19
Eli Lilly
LLY
$657B
| $37.7M | 1.47% | 486,865 +103,766 | +27% | +$8.03M |
|
|
20
Bristol-Myers Squibb
BMY
$96B
| $33.3M | 1.29% | 525,722 +176,601 | +51% | +$11.2M |
|
21
Humana
HUM
$36.5B
| $31.9M | 1.24% | 118,733 -19,823 | -14% | -$5.33M |
|
22
Thermo Fisher Scientific
TMO
$186B
| $30.5M | 1.19% | 147,855 +9,887 | +7% | +$2.04M |
|
23
Idexx Laboratories
IDXX
$51.8B
| $29.3M | 1.14% | 153,076 +20,724 | +16% | +$3.97M |
|
24
Novartis
NVS
$245B
| $28.4M | 1.1% | 351,020 -30,862 | -8% | -$2.5M |
|
25
Sarepta Therapeutics
SRPT
$1.78B
| $28M | 1.09% | 378,516 +44,116 | +13% | +$3.27M |
|